ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Thursday, May 26, 2022
Submitted by
Source
Source Name: The New England Journal of Medicine
No statistical significance ,between the two arms, regarding the OVERALL survival in this RCT funded by the supplier and manufacturer of the immunotherapy in question....
Printer-friendly
